Ritter Pharmaceuticals (RTTR) Earns News Sentiment Rating of 0.09
News stories about Ritter Pharmaceuticals (NASDAQ:RTTR) have trended somewhat positive recently, Accern Sentiment reports. The research group rates the sentiment of news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Ritter Pharmaceuticals earned a coverage optimism score of 0.09 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.2295261779095 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Guide to Trend Direction: Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR) – The Investor Guide (wallstreetnews24.com)
- Stock Views And Recommendations: Pandora Media, Inc. (NYSE:P), Ritter Pharmaceuticals, Inc. (NASDAQ:RTTR … – Market Breaking Point (press release) (journalfinance.net)
- Ritter Pharmaceuticals, Inc. (RTTR) registers a price change of -29.31% while Health Insurance Innovations, Inc … – Stocks Gallery (stocksgallery.com)
- Ritter Pharmaceuticals, Inc. (RTTR) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Ritter Pharma (RTTR) Prices $23M Public Offering (streetinsider.com)
Shares of Ritter Pharmaceuticals (NASDAQ:RTTR) traded up 3.1714% during midday trading on Monday, reaching $0.3611. 1,674,380 shares of the company’s stock traded hands. Ritter Pharmaceuticals has a 52-week low of $0.34 and a 52-week high of $3.75. The firm’s market cap is $5.33 million. The company has a 50 day moving average of $0.55 and a 200 day moving average of $0.55.
Ritter Pharmaceuticals (NASDAQ:RTTR) last released its earnings results on Monday, August 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.14). On average, equities analysts predict that Ritter Pharmaceuticals will post ($0.42) EPS for the current fiscal year.
RTTR has been the topic of a number of recent research reports. Zacks Investment Research lowered Ritter Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday. Chardan Capital cut their target price on Ritter Pharmaceuticals from $3.50 to $1.50 and set a “buy” rating on the stock in a research note on Tuesday, August 8th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average price target of $4.83.
COPYRIGHT VIOLATION WARNING: This piece was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.thecerbatgem.com/2017/10/02/ritter-pharmaceuticals-rttr-earns-news-sentiment-rating-of-0-09.html.
Ritter Pharmaceuticals Company Profile
Ritter Pharmaceuticals, Inc develops therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. The Company’s segment is focusing on the development and commercialization of RP-G28. The Company conducts human gut health research by exploring metabolic capacity of the gut microbiota and translating the functionality of prebiotic-based therapeutics into applications intended to have impact on a patient’s health.
Receive News & Stock Ratings for Ritter Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.